Preclinical ReportsEffect of miR-196a inhibition on esophageal cancer growth in vitroBai, Minghuaa,,b; Dong, Yipinga; Zhou, Congyaa; Sun, Xiaoa; Ma, Jinlua; Han, SuxiaaAuthor Information aDepartment of Oncology, the 1st Affiliated Hospital, Xi’an Jiaotong University bDepartment of Oncology, the 2nd Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China Received 11 November 2018 Revised form accepted 7 July 2019 Correspondence to Suxia Han, Department of Oncology, the 1st Affiliated Hospital, Xi’an Jiaotong University, Yan Ta West Road 277, Xi’an, Shaan’xi, 710061, China, Tel/fax: +86 29 8532 4019; e-mail: firstname.lastname@example.org Anti-Cancer Drugs: February 2020 - Volume 31 - Issue 2 - p 169-176 doi: 10.1097/CAD.0000000000000823 Buy Metrics Abstract Esophageal cancer has recent shown a higher incidence but lower 5-year survival rate after normal clinical treatment in China. The aim of this study was to observe whether the inhibition of miR-196a affects esophageal cancer cell growth by modulating the nuclear factor-κB target gene and to detect the possible cooperative therapeutic effects on esophageal cancer by knocking down miR-196a expression combined with the specific inhibitor of nuclear factor-κB target genes. Thus, anti-miR-196a or sotrastaurin, a protein kinase C (PKC) inhibitor, were used to alter PKC expression. We found that miR-196a knockdown or PKC inhibition by sotrastaurin changed PKC expression which then reduced esophageal cancer cell proliferation and downregulated proliferating cell nuclear antigen expression via the classical B-cell receptor-PKC nuclear factor-κB pathway but not the alternative pathway; in addition, miR-196a inhibition can increase the caspase level and induce esophageal cancer cell apoptosis. Our current results provided the evidence that miR-196a was related to the classical nuclear factor-κB pathway, and these new findings proved the potential therapeutic effect of miR-196a in targeted therapy for clinical esophageal cancer patients. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.